Defects in CB cellular immunity (Cairo, et al, Blood 82:2269, 1993) and cytokine production (Cairo, et al, Pediatr Res 30:326, 1991; 31:574, 1992; Lee & Cairo, et al, Blood 86:163a, 1995) may contribute to the decreased incidence of GvHD post cord blood transplantation, and potentially increase the relapse rate post transplant. Interleukin-15 is a novel cytokine that has no sequence homology to IL-2, but requires the use ofβ- and γ-chains of the IL-2 receptor complex for signaling. IL-15 shares many of the T cell stimulatory activities described for IL-2 (Armitage, et al, J Immunol 154:483, 1995). Recent studies have demonstrated induction of LAK cell activity in adult peripheral blood (aPBL) by IL-15 against known tumor targets (Grabstein, et al, Science 264:965,1994). Sweetman, et al, have demonstrated decreased IL-15 expression in cord MNC vs. adult MNC (Sweetman, et al, SPR abstract, 1996). In this study we sought to determime the effects of IL-15 on LAK cells generated from CB by comparing with IL-12 and IL-2 and aPBL. Mononuclear cells were isolated by density gradient separation, and monocytes were depleted by plastic adherence. LAK cells were generated by stimulating the non-adherent cells with IL-15 for 72 hours followed by a standard 3-hr 51Cr-release cytotoxicity assay against Daudi, a Burkitt's lymphoma cell line. LAK cell cytotoxicity against Daudi cells was shown to be dose-dependent, 93 ± 31 Lytic Unit (LU) for 0.1ng/ml, 343 ± 76 for 1.0, 774 ± 116 for 10, 1036 ± 195 for 100, and 1302 ± 311 for 500 ng/ml (n=5). The peak cytotoxic activity was reached with 100 ng/ml IL-15, similar to the activity generated with 1000 u/ml IL-2 (1090 ± 245 LU, n=3, p=0.886), and higher than 100 u/ml IL-12 (381 ± 89 LU, n=3, p=0.035). When compared to aPBL, CB cells show significantly increased response to IL-15 stimulation at the lower doses of 1 ng/ml (343 vs 90 LU, p=0.033) and 10 ng/ml(774 vs 357, p=0.036), but no significant difference at 100 ng/ml (p=0.324). The LAK cells generated from CB with 10 ng/ml IL-15 produced a wide tumorcidal spectrum against LAK-nonsensitive tumor cells, including acute lymphoblastic leukemia cell lines CCRF-CEM (T cells) (318 ± 3 LU vs 110 ± 39 for media control) and CCRF-SB (B cells) (436 ± 114 vs 36 ± 12), and neuroblastoma cell lines NB-100 (330 ± 40 vs 67 ± 31) and SK-N-MC (358 ± 13 vs 100 ± 30). Our data suggests that IL-15 is able to induce a LAK response from CB cells comparable to aPBL and at low doses generating a higher response in the cord vs. the adult. This effect with IL-15 was equal to high doses of IL-2 and higher than levels seen using IL-12, thus suggesting a possible use for cancer immunotherapy following cord blood transplantation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Qian, J., Knoppel, E., van de Ven, C. et al. INTERLEUKIN-15 AUGMENTS LAK CELL ACTIVITY GENERATED FROM HUMAN UMBILICAL CORD BLOOD (CB). † 1726. Pediatr Res 39 (Suppl 4), 290 (1996). https://doi.org/10.1203/00006450-199604001-01750
Issue Date:
DOI: https://doi.org/10.1203/00006450-199604001-01750